All In Biotech

Drug Trial Radar · NCT01144338

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus.

Last checked: Nov 20, 2026Latest source record: Aug 8, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 14,752 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

14,752

Actual

Start

Jun 18, 2010

Primary completion

Apr 21, 2017

Study completion Apr 24, 2017

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 15, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare the impact of including exenatide once weekly in addition to usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary composite endpoint of cardiovascular-related death, nonfatal myocardial infarction (MI), or nonfatal stroke.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • Exenatide Once WeeklyDrug

    Subcutaneous injection, 2 mg, administered once weekly.

  • PlaceboDrug

    Subcutaneous injection, matching volume of placebo, administered once weekly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Efficacy Outcome MACE EventsTime frame: Time to first event. Information collected during study period (anticipated to be up to 7.5 years).
  2. Primary Safety Outcome MACE EventsTime frame: Time to first event. Information collected during study period (anticipated to be up to 7.5 years).

Locations

629 sites in 35 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Glendale, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Jonesboro, Arkansas

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Chula Vista, California

  • Research Site

    Concord, California

  • Research Site

    Escondido, California

  • Research Site

    Fullerton, California

  • Research Site

    Greenbrae, California

  • Research Site

    La Mesa, California

  • Research Site

    Laguna Hills, California

  • Research Site

    Long Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    Northridge, California

  • Research Site

    Oceanside, California

  • Research Site

    Orange, California

  • Research Site

    Redondo Beach, California

  • Research Site

    San Diego, California

  • Research Site

    San Diego, California

  • Research Site

    Sylmar, California

  • Research Site

    Torrance, California

  • Research Site

    Tustin, California

  • Research Site

    Victorville, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Littleton, Colorado

  • Research Site

    Thomaston, Connecticut

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Cape Coral, Florida

  • Research Site

    Fort Lauderdale, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Sarasota, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Decatur, Georgia

  • Research Site

    Marietta, Georgia

  • Research Site

    Roswell, Georgia

  • Research Site

    Pocatello, Idaho

  • Research Site

    Chicago, Illinois

Showing 40 of 629 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.